HST 1021
Alternative Names: HST-1021Latest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator HotSpot Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 23 Oct 2024 Pharmacodynamics data from the preclinical studies in Nasopharyngeal cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR)
- 20 Jun 2024 Pharmacodynamics and adverse event data from the preclinical studies in haematological malignancies and solid tumours released by HotSpot Therapeutics
- 11 Dec 2023 Pharmacodynamics data from a preclinical studies in Haematological malignancies released by HotSpot Therapeutics